Cell Source, Inc.

CLCSSEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1569340

Concept	FY2023	FY2022	FY2021	FY2020	FY2019
Research and Development Expense	—	$1.3M	$834.9K	$2.5M	$274.9K
Selling, General and Administrative Expense	—	—	—	—	—
Operating Expenses	$4.2M	$4.0M	$3.6M	$3.8M	$2.0M
Operating Income (Loss)	-$4.2M	-$4.0M	-$3.6M	-$3.8M	-$2.0M
Interest Expense	—	—	—	$228.8K	-$219.1K
Nonoperating Income (Expense)	-$992.4K	-$1.5M	-$922.1K	-$670.3K	-$111.3K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$5.2M	-$5.5M	-$4.6M	—	—
Income Tax Expense (Benefit)	—	—	—	$0.00	—
Net Income (Loss) Attributable to Parent	-$5.2M	-$5.5M	-$4.6M	-$4.5M	-$2.1M
Earnings Per Share, Basic	-$0.18	-$0.19	—	—	—
Earnings Per Share, Diluted	-$0.18	-$0.19	—	—	—

Concept	FY2023	FY2022	FY2021	FY2020	FY2019
Assets	$409.8K	$313.8K	$452.3K	$114.8K	$65.8K
Assets, Current	—	—	$448.8K	—	—
Cash and Cash Equivalents, at Carrying Value	—	$93.1K	$241.6K	$18.9K	$18.9K
Liabilities	$13.0M	$10.1M	—	$5.9M	$5.0M
Liabilities, Current	—	—	$8.4M	$5.7M	$5.0M
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$680.3K	$223.0K	$193.1K	$135.4K	$277.8K

Concept	FY2023	FY2022	FY2021	FY2020	FY2019
Net Cash Provided by (Used in) Operating Activities	-$3.1M	-$3.4M	-$2.8M	-$2.6M	-$2.0M
Net Cash Provided by (Used in) Financing Activities	$3.3M	$3.2M	$3.0M	$2.6M	$1.6M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)